4D Molecular Therapeutics FDMT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's total equity?
- 4D Molecular Therapeutics (FDMT) reported total equity of $451.84M in Q1 2026.
- How has 4D Molecular Therapeutics's total equity changed year-over-year?
- 4D Molecular Therapeutics's total equity decreased by 3.8% year-over-year, from $469.72M to $451.84M.
- What is the long-term trend for 4D Molecular Therapeutics's total equity?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's total equity has grown at a 14.5% compound annual growth rate (CAGR), from $256.39M to $505.66M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.